Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
Clinical trial NCT02782741 · COMPLETED
Trial details
- NCT number
- NCT02782741
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-02
- Primary completion
- 2020-03-19
- Enrollment
- 101
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.